Newsletter
October 28, 2014
Newsletter 2014.07 – ANVISA publishes resolutions on new procedures relative to marketing authorization in Brazil: RDC #58 and #60/2014
The main law regulating the health system in Brazil – Law #6,360 dated 1976 – establishes that each and every drug available in the pharmaceutical market must be approved by the Ministry of Health. Since the creation of the Brazilian FDA (called ANVISA), this autonomous autarchy subordinated to the Ministry of Health is in charge of issuing marketing authorization for drugs for human use and of establishing specific resolutions in order to regulate each of the existing categories of medicaments, such as the new drugs, generics, similars, biologicals.
According to ANVISA’s requirements, the documentation submitted by the manufacturers of both generic and similar drugs, upon applying for marketing approval, is significantly simplified compared to the reference product (the so-called “abridged process”), as only pharmaceutical equivalence and relative bioavailability/ bioequivalence assays are required to obtain approval for products pertaining to these categories.
It should be noted that, since the publication of Resolutions RDC #133 (new applications for marketing approval) and RDC #134 (similars, already approved), both dated May 29, 2003, ANVISA has begun to require proof of therapeutic equivalence also for similar drugs; therefore, it is estimated that all manufacturers of these products will have complied with such requirement by the end of 2014.
Accordingly, studies of pharmaceutical equivalence and bioavailability/bioequivalence became necessary in order to obtain marketing authorization for both generic and similar drugs, although the latter were not then yet considered to be interchangeable with the reference product.
Last related news
September 24, 2024
Brazilian CNPQ defines Intellectual Property guidelines for funded inventions
The Brazilian National Council for Scientific and Technological Development (CNPQ), through CNPQ Ordinance No. 1,935 (“Ordinance”), dated September 20, 2024, has established … Brazilian CNPQ defines Intellectual Property guidelines for funded inventions
September 19, 2024
Updates on procedures for ownership transfers and amendments to patent holder informations
Updates on procedures for transferring ownership and changing the name/company name, address/headquarters, and security interest or pledge of patent holders of any … Updates on procedures for ownership transfers and amendments to patent holder informations
September 19, 2024
Brazilian Superior Court decides on the non-remunerative nature of stock option plans
On September 11, 2024, in its ruling on Case No. 1226, the Brazilian Superior Court (STJ) determined that gains derived from stock … Brazilian Superior Court decides on the non-remunerative nature of stock option plans